Production Capacity and Market Demand - The company plans to increase production capacity by 800 tons of BA (Dexamethasone) and 200 tons of Progesterone, responding to the growing market demand for steroid hormone drugs [9]. - The company is actively preparing to expand its market presence to ensure the successful absorption of new production capacity [9]. - The domestic market for steroid drugs is experiencing a continuous demand increase, with international sales growing at an annual rate of 10%-15%, making steroid drugs the second largest category after antibiotics [45]. - The steroid hormone drug market is experiencing continuous growth, with global sales exceeding $150 billion in 2020, indicating strong demand for steroid hormone intermediates and raw materials [35]. - The company is positioned to become a global production center for steroid hormone raw materials and intermediates, given its current production capacity [35]. Financial Performance - The company's operating revenue for 2021 was ¥590,885,338.44, representing a 26.23% increase compared to ¥468,117,263.96 in 2020 [25]. - The net profit attributable to shareholders for 2021 was ¥78,330,635.77, a 46.99% increase from ¥53,288,521.48 in 2020 [25]. - The net cash flow from operating activities reached ¥58,004,300.45, marking a significant increase of 330.46% from ¥13,474,987.99 in 2020 [25]. - The total assets at the end of 2021 amounted to ¥1,211,243,283.36, a 50.57% increase from ¥804,426,535.29 at the end of 2020 [25]. - The company reported a basic earnings per share of ¥0.74 for 2021, up 19.35% from ¥0.62 in 2020 [25]. Research and Development - R&D investment accounted for 6.28% of total revenue, with a stable core technology team in place [56]. - The company has established three new R&D centers to enhance its research capabilities and focus on high-end steroid drug development [57]. - The company completed the R&D of several new products, including the high-end progesterone intermediate and the new process for progesterone, which are expected to enhance product lines and competitiveness [69]. - The company aims to enhance its research and development capabilities, with a focus on new products and processes, leveraging its R&D centers in Hangzhou and Wuhan [96]. - Research and development investments increased by 25% in 2021, focusing on innovative drug formulations and delivery systems [181]. Environmental Management - The company emphasizes environmental protection and has established a comprehensive environmental management system, ensuring compliance with national standards and reducing pollution [8]. - The company acknowledges the increasing environmental governance costs due to stricter regulations and is prepared to invest in compliance measures [7]. - The company has implemented a wastewater treatment process that includes acid-base pre-treatment and a series of treatment stages, ensuring compliance with environmental standards [163]. - The company has established a strict hazardous waste management system, ensuring compliance with regulations and proper disposal of hazardous materials [167]. - The company has not faced any environmental pollution incidents or regulatory penalties during the reporting period, demonstrating compliance with environmental laws [168]. Corporate Governance - The company maintains complete independence in operations, assets, personnel, finance, and institutions from its controlling shareholders [116]. - The company has a fully independent financial department with a standardized accounting system and independent bank accounts, ensuring no shared accounts with controlling shareholders [120]. - The company has a well-established corporate governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team [121]. - The company complies with all relevant laws and regulations regarding corporate governance, with no significant discrepancies noted [115]. - The company has established a dedicated "Investor Relations" section on its official website to maintain good communication with investors [115]. Employee Management - The company has established a comprehensive salary system and incentive mechanism to ensure employee interests are protected [146]. - The company emphasizes employee training, with a structured training system that includes both internal and external training programs [147]. - The total number of employees at the end of the reporting period was 481, with 151 in the parent company and 330 in major subsidiaries [145]. - The company has a focus on research and development, providing project incentive bonuses to employees based on their contributions to technological improvements [146]. - The company has a strict internal control system in place, with no significant deficiencies identified in financial reporting during the reporting period [151]. Strategic Plans and Future Outlook - The company plans to officially launch its fundraising projects by the end of 2022, including the completion of construction for the joint project with Huahai [92]. - The company aims to strengthen its market position in the hormone raw material and intermediate sectors, targeting a top-tier position in the next five years [93]. - The company plans to optimize its market layout by consolidating existing advantages and developing new emerging areas [94]. - The company expects a revenue growth guidance of 10% to 12% for the upcoming fiscal year, driven by new product launches and market expansion strategies [182]. - The company provided a future outlook projecting a revenue growth of 10% for 2022, aiming for 1.32 billion yuan [179].
共同药业(300966) - 2021 Q4 - 年度财报